A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer

  • Cancer
  • Cervical Cancer
Please note that the recruitment status of the trial at your site may differ.
Trial Status:

Completed

This trial runs in
Cities
  • Buenos Aires
  • dtb
  • La Rioja
  • Lomas de Zamora
  • Mar del Plata
  • Resistencia
  • Rosario
  • San Miguel de Tucumán
  • San Salvador de Jujuy
  • Santa Fe
  • Villa Mercedes
Trial Identifier:

NCT03071848 ML39360

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the safety of bevacizumab (Avastin®) combined with standard chemotherapy in participant with advanced cervical cancer, with special focus on the incidence of gastrointestinal (GI) and genitourinary (GU) fistulas and GI perforations in the common practice setting.

      Hoffmann-La Roche Sponsor
      NCT03071848,ML39360 Trial Identifier
      No Intervention Treatments
      Cervical Cancer Condition
      Official Title

      Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin®) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer

      Eligibility Criteria

      Female Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Age 18 or older
      • Diagnosis of primary stage IVB, recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy
      • Retrospective clinical decision made to initiate therapy with bevacizumab (Avastin®) combined with standard chemotherapy (cisplatin or carboplatin or topotecan and paclitaxel) between 01 January 2015 and 01 January 2016
      • All participants must have received at least one dose of bevacizumab combined with standard chemotherapy between 01 January 2015 and 01 January 2016 AND have at least 12 months of documented follow up, from treatment start, unless died or lost to follow up within the minimum study entry follow up period
      • Availability of documentation of for advanced cervical cancer (including prior treatment as applicable) and follow up in the participant's medical records
      Exclusion Criteria
      • Participation during the study period in an interventional clinical trial or any other interventional study that may impact advanced cervical cancer outcome
      • Participants who have received prior therapy with any anti-VEGF drug, including bevacizumab

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now